BioSpace News Archive

Once-daily system complements Avenova and leverages salesforce calls on eyecare specialists

The Ontario Lung Association report, Helping the Missing Million, aims to improve the diagnosis and treatment of COPD in Canada

Nuventra Pharma Sciences is pleased to announce the addition of Iftekhar Mahmood, Ph.D., to its growing team of experienced consultants. Dr. Mahmood has more than 25 years of clinical pharmacology experience at the FDA..

Castle Biosciences, Inc. announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on Monday, November 11, 2019.

VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of Directors and all of its committees in order to increase their focus on other personal business interests.

Endo International plc (NASDAQ: ENDP) announced that Endo Aesthetics launched a “Redefining Scientific Artistry” campaign at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) held in Chicago, IL from October 24 - 27, 2019

VITAS® Healthcare, the nation’s leading provider of end-of-life care, has named Rory Farrand as director of VITAS® Palliative Care.

Daré Bioscience, Inc., a leader in women’s health innovation, and Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, announced a poster presentation at the Sexual Medicine Society of North America 20th Annual Fall Scientific Meeting, which took place in Nashville, Tennessee, October 24-27, 2019.

BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that company CEO Peter Altman, PhD, is scheduled to present at the Dawson James Securities Small Cap Growth Conference on Tuesday, October 29, 2019, at 4:30pm EST in Preserve Ballroom C at the Wyndham Grand Hotel in Jupiter, Florida.

Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS).